Published in final edited form as:

J Addict Dis. 2010 April ; 29(2): 200–216. doi:10.1080/10550881003684798.

Pharmacotherapy in the Treatment of Addiction: Methadone

Mary Jeanne Kreek, M.D., Lisa Borg, M.D., Elizabeth Ducat, N.P., and Brenda Ray, N.P.

Laboratory of the Biology of Addictive Diseases, The Rockefeller University

Abstract

Methadone maintenance treatment is the most widely available pharmacotherapy for opioid addiction and has been shown over a period of 40 years to be an effective and safe treatment. While women comprise approximately 40% of clients currently being treated in MMT programs, comparatively little research geared specifically toward this group has been published. This article begins with an overview of neurobiological studies on opioid addiction, including a discussion of gender differences, followed by a review of the pharmacology of methadone. The authors then examine the particular needs and differences of women being treated in MMTs, including co-dependence with other substances, women's health issues and psychosocial needs unique to this population. In conclusion, research shows that women have different substance abuse treatment needs in comparison to their male counterparts. One New York City MMT program that has attempted to address these differences is highlighted.

Keywords

women; methadone maintenance; pharmacotherapy; gender differences; addiction; opiate addiction

INTRODUCTION

During the initial development of the first effective pharmacotherapy for an addictive disease, a treatment which remains the most effective and most widely used in the United States and worldwide, methadone maintenance treatment (MMT) for heroin addiction, the initial decision was to study only very severely impaired persons, and only male opiate addicts, because of the special potential complexities of females in reproductive years. Therefore, in the first research done at the Rockefeller Hospital in the then Rockefeller Institute for Medical Research in 1964 (the original work published with the transcription of the discussion at the Association of American Physicians meeting¹, and also in the Archives of Internal Medicine²), no women were studied. Similarly in the one-year follow-up of our patients admitted to the Rockefeller Hospital in 1964, along with several new patients admitted and followed for two weeks to three months at Manhattan General Hospital, no women were included³. We set the criteria for admission of subjects for study, criteria that were reviewed by the hospital ethics board at that time: all male subjects; all with a history of short-acting opiate abuse with multiple daily self-administrations for four years or longer; and all with failures at least three times in abstinence-based treatment or in prison with prompt relapse. It was not until 1967, after three years of research had taught us the effectiveness and also the safety of MMT, that the first women were admitted into treatment research.

*Reprint requests to: Mary Jeanne Kreek, M.D., Professor and Head, The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, Senior Physician, The Rockefeller University Hospital, 1230 York Avenue, New York, NY 10065, Tel: (212) 327-8490, Fax: (212) 327-8574, kreek@rockefeller.edu.

Over subsequent years, the numbers of women in MMT sharply rose to the current levels of about 40% females and 60% males in most clinics, reflecting the percentages of opiate addicts in the general population and in all ethnic and cultural groups. Overall, neither we nor other groups have found important biological, pharmacokinetic, or pharmacodynamic differences between females and males in MMT studies. Further, in carefully conducted basic clinical research or applied clinical research studies, very few differences have been reported in terms of the clinical outcome, physiological effects, or pharmacological effects between women versus men in either MMT or in buprenorphine-naloxone treatment.

However, of course, women have special needs, most of which are due to very discrete issues that make women different from men. The most obvious and important, and which we began to address in the early 1970s, was the fact that early on we documented that pulsatile luteinizing hormone (LH) is profoundly blunted by cycles of heroin and other short-acting opiate abuse, and that normalization of this neuroendocrine function occurs within one year of steady-dose MMT⁴. Also, it was quickly ascertained that women who had had hypomenorrhea or secondary amenorrhea during cycles of heroin and other short-acting opiate addiction had a very low fecundity rate at that time, despite the fact that many had derived their income primarily from prostitution and had very frequent sexual exposures without protection. However, with stabilization in MMT, normal menstrual cycles returned and, with the increasing normalization of their lifestyles and social status, many women wished to become pregnant. Therefore, extensive studies were conducted to determine both the impact of MMT on females during pregnancy and on neonates, with minimal neonatal abstinence found in some, but far from all, babies born of mothers maintained on even very high doses of methadone in treatment^{5, 6, 7, 8, 9, 10}. The later outcome of the children appears to be normal, but these studies are very complex because of the various social and environmental factors involved. In our laboratory we conducted several sets of studies on the metabolism of methadone during pregnancy, in which we showed an acceleration of biotransformation of methadone during the third trimester, due to progesterone effects with prompt restoration to normal metabolism of methadone in the postpartum period⁶. Further, we conducted two studies of the appearance of methadone in breast milk and found, as predicted, due to the very tight plasma protein binding of methadone, that very small amounts of methadone appear in breast milk, too small to have any negative impact, and also too small to treat any signs and symptoms of opiate withdrawal in this population. These studies are briefly reviewed in this chapter (and also reviewed in the chapter on pregnancy and methadone maintenance treatment)^{5, 6, 7, 8, 9, 10}.

In all of our extensive basic clinical research addressing the molecular neurobiological aspects of opiate addiction, and further in our human molecular genetic studies of opiate addiction, we have found very few differences between males and females. These will be briefly outlined below. However, the additional obvious needs of women are related to their roles in society, including child bearing, child rearing, and home maintenance, along with the special needs of women brought about by the very different views of the roles and value of women in different theaters of our Western society. Several of these special issues will be discussed below, along with brief presentations of the relative proportion of men and women experiencing the various special concerns commonly encountered during MMT.

Molecular Neurobiological Studies: Gender Differences

Over the years, our laboratory has conducted numerous basic clinical research studies in the context of opiate use in which we have probed the function of the brain, as well as integrated neuroendocrine physiology, by conducting a variety of rigorous tests, some of which are standard tests and others of which are provocative tests of various types which we have developed. Many of these tests have been designed to study the stress-responsive hypothalamic-pituitary-adrenal axis (reviewed in 11, 12, 13).

However, in only one of these studies have we found an interesting difference between males and females. This difference occurred in a series of studies in which we used the shortened form of the dynorphin A(1–13) of the natural kappa opioid ligand dynorphin A(1–17), approved for use under an FDA investigator-initiated IND, to probe the tuberoinfundibular dopaminergic system^{14, 15}. In these studies two doses of dynorphin A(1–13) were administered to healthy volunteers and, on a third day, a placebo was administered. In these studies, we used serum prolactin levels as a biological marker for dopaminergic tone in the tuberoinfundibular dopaminergic system, since in humans and non-human primates prolactin release is almost exclusively under tonic inhibition by dopamine. Therefore, when dopaminergic tone is reduced, serum prolactin levels promptly rise. It has been shown that this effect is mediated primarily through the dopamine D2 receptors in the hypothalamus. We found a dose-dependent response to the two doses of dynorphin in healthy human volunteers. However, when we looked at the results in healthy females as opposed to healthy males, even though we had a relatively small number of healthy females, we found significant differences. The females had a greater response to dynorphin administration, as shown through a greater rise, and thus a greater peak, of prolactin levels and area under the plasma concentration time curve. We therefore analyzed those studies in female subjects separately¹⁴. In our next set of studies, we looked at dopaminergic tone in long-term successfully maintained MMT subjects, all of whom had a history of short-acting opiate, primarily heroin, dependency¹⁵. Again, in these studies, because we had found a significant difference in the two genders in healthy subjects, we began our studies with males in MMT and then added another group of healthy control volunteer males. Again, we found a dose-dependent rise in serum prolactin levels, reflecting a dose-dependent lowering in dopaminergic tone. However, the peak levels in the area under the plasma concentration curve of prolactin were significantly lowered in methadone-maintained former heroin-addicted males than in normal volunteer males¹⁵. Currently, we are conducting gender-specific studies in methadone-maintained females as well as cocaine-dependent females. In each case, studies in each gender will be conducted.

Human Molecular Genetics

Since 1994, our laboratory has been studying the human molecular genetics related to each of three different addictive diseases, opiate addiction, and cocaine addiction, without and with codependence with alcohol. To date, we have found association of many specific gene variants with a history of severe heroin dependence, with most studies conducted with long-term methadone-maintained former heroin addicts. In each of these studies, we have analyzed potential differences between males and females and have found none¹⁶. One of our major focuses has been genetics related to both heroin addiction and alcoholism, considering stress responsivity as a covariable. This work has been extensively reviewed recently^{17, 18}. We discovered, in collaboration with Lei Yu, a relatively common variant to the human mu opioid receptor in the coding region, specifically in the N-terminus where opioids and opiates bind¹⁹. This variant is functionally different from the prototype in molecular and cell biological studies. Later, our group and many others have shown that presence of this variant alters stress responsivity in healthy humans^{17, 18, 19}. Further, we have shown that this variant is associated with heroin addiction and also alcoholism in two separate studies conducted in a relatively non-admixed population^{20, 21}.

In one study, we addressed a question of whether or not baseline levels of the stress-responsive hormones were different in healthy subjects with this variant. We found that male and female healthy control subjects with one or two copies of this A118G variant, which alters mu opioid receptor protein, had higher basal levels of cortisol when studied in a stress-minimized environment, though these levels did not exceed the upper limits of normal²². In these studies, we found a small but non-significant difference in females' cortisol levels, compared to healthy males²². Specifically, there was a trend, but not a significantly higher level, of basal cortisol

in females with one or two copies of this A118G variant producing a functionally different mu opioid receptor.

The only one of our specific hypothesis-driven studies of the human molecular genetics that has yielded gender differences is in the catechol-*O*-methyl transferase gene (*COMT*)²³. In this study, we found that a very common and functional variant of the *COMT* gene is significantly associated with heroin addiction, but only in Hispanic subjects²³. Further, this association was also found in female subjects of Hispanic origin when analyzed separately. Since this is quite an admixed population, further studies are essential to determine whether this finding can be replicated.

Thus, most of the differences in females discussed below are related to their basic reproductive biological differences, as well as differences in their roles in culture and society. However, it is important to continue to address this question, especially related to special needs that might be encountered by women as they enter methadone maintenance or buprenorphine maintenance treatment for short-acting opiate addiction, whether it be heroin addiction or prescription opiate addiction.

Pharmacology of Methadone

Methadone was approved by the US Food and Drug Administration (FDA) in 1972 as a treatment for opioid addiction. Opioids are all compounds which are related in function to opium, which is derived from poppies (as reviewed in 24). Opiates are those compounds with opioid-like activity and which are directly derived from natural poppy plant thebaine structure compounds, such as morphine and codeine. Methadone is a structurally dissimilar or synthetic opioid, which has two enantiomers found in equal amounts in a racemic mixture; the active *l* (R) enantiomer has a half-life of 36–48 hours and the inactive *d*(S) enantiomer has a half-life of approximately 16 hours^{25, 26, 27}. Methadone is also used very effectively in the treatment of chronic pain. Methadone meets the two important criteria for a maintenance treatment: high systemic bioavailability (>90%)²⁸ when given orally and long half-life with long-term treatment²⁹. Methadone is rapidly absorbed by the oral route with a delayed onset of action, detectable in plasma at 30 minutes with peak levels at 2–4 hours with sustained levels maintained over 24 hours^{25, 30, 31, 32, 33}. Methadone also has N-methyl-D-aspartate (NMDA) receptor antagonist properties, which affect the development of tolerance³⁴.

During MMT, methadone levels are relatively constant due to slow release of methadone into the blood from hepatic stores^{35, 36}. Methadone is greater than 90% plasma protein bound in the bloodstream and is also redistributed into lipid stores, which are among the reasons that MMT is effective as a once per day, oral treatment for heroin addiction³⁰. This is in contrast to heroin and morphine, which have a rapid onset of action and are short-acting³⁷. Methadone has both low abuse liability and reward effect due to its slow onset and offset.

Due to the long half-life of methadone, an initial maintenance dose should usually start with 20–40mg/daily; then the dose is gradually increased, since a dose increase greater than the rate of development of tolerance can result in accumulation which can lead to sedation and respiratory depression. Doses must be raised slowly, usually by 10 mg every 4–7 days. Patients in effective MMT receiving appropriate doses (80–150 mg per day) and adequate blood levels (250–400 ng/ml) still may have symptoms of withdrawal toward the end of the dosing interval³⁸. These symptoms may be due to drug interactions (e.g., phenytoin, rifampin or alcohol consumption of >4 drinks/day), but in this case lower plasma levels are found at the end of a 24h dosing interval^{39, 40, 41, 42}. Alternatively early abstinence symptoms may be due to undefined pharmacodynamic factors (those determining response to the drug), or other factors such as medical or psychological comorbidity³⁸, such as depression, which has been found to be more prevalent in women in MMT⁴³. When relatively high doses of methadone

do not result in apparent therapeutic levels, this may be due in part to individual genetic factors, although these have not been well elucidated, or undefined drug interactions usually due to clandestine use of alcohol^{32, 44, 45}.

Methadone is metabolized in the liver by the cytochrome P450-related enzyme systems (mostly the CYP3A4 and, to a lesser degree, the CYP2D6, CYP2B6, and CYP1A2 systems) to two biologically inactive metabolites, a pyrroline and a pyrrolidine, which are then further metabolized^{27, 46}. Methadone and its metabolites are excreted nearly equally in urine and in feces^{47, 48, 49, 50, 51}. The amount of methadone excreted in the urine is modestly affected by urine acidity. In patients with renal impairment, methadone can be metabolized almost completely by the gastrointestinal system^{47, 48, 49, 50}. This reduces potential toxicity by avoiding accumulation. In peritoneal dialysis, less than 1% of methadone is cleared, probably because it is extensively protein bound, and also due to the small degree that methadone is actually found in the blood at any given time⁴⁹. Patients with severe chronic liver disease have decreased methadone metabolism, thus slower metabolic clearance of methadone, yet lower than expected plasma methadone levels for a given dose due to lower hepatic reservoirs of methadone because of reduced liver size⁵². Methadone metabolism is relatively normal in the presence of mild to moderate liver dysfunction^{36, 50}.

Drug-drug interactions with methadone have been well-documented⁴¹. The major categories of drugs which may interact with methadone include both inducers and inhibitors of the hepatic cytochrome p450-related enzyme system, mostly CYP3A4, as well as inhibitors of CYP2D6 (reviewed in 27). However, few of these medications (e.g., rifampin, phenytoin)^{39, 40, 41, 40} have been shown to have an actual significant drug interaction effect at the therapeutic dose of each second medication, and most medications which have been hypothesized to have an interaction, when studied, have no interaction effect: e.g., disulfiram⁵³.

Pharmacokinetic interactions occur with methadone and specific antiretroviral medications prescribed in the treatment of human immunodeficiency virus (HIV-1). These interactions are usually via the CYP3A4 system and can have effects on the level of either methadone or the antiretroviral medication, which can then have actual clinical effects (reviewed in 54). Alfa-2b interferon given as treatment for hepatitis C, which is common in intravenous drug users (IVDUs), does not appear to have any clinically significant interaction in terms of subjective or objective effects, as noted in three studies^{55, 56, 57}; however, in all patients interferon produces flu-like symptoms which may mimic opioid withdrawal.

Methadone levels are affected by the regular high intake of >4 alcoholic drinks/day. When blood measures of ethanol are acutely elevated (>150mg/dl) increased levels of methadone can be anticipated. However, whenever alcohol is no longer present in the body at these high levels, and there are no longer high doses of alcohol, methadone levels may be lower due to induction of the P450 enzymes (reviewed in 58, 59).

Methadone metabolism is significantly accelerated in the third trimester of pregnancy, and methadone doses often need to be increased at that time to prevent withdrawal symptoms and drug-seeking behavior (e.g., 60). During pregnancy methadone may need to be given twice daily (in divided doses) due to differences in elimination, absorption and clearance⁶¹. Methadone crosses the placenta and is metabolized mainly by the placental enzyme aromatase/CYP19, which has large inter-individual variability in its activity. Nanovskaya⁶² and Hieronymous and colleagues⁶³ suggest that this variability may be a factor related to both the presence and severity of neonatal abstinence syndrome (NAS). Studies have shown a clear relationship to time of dosing of methadone and breast milk levels of methadone, although the levels in breast milk are very low at all times because of the extensive plasma protein binding of methadone^{4, 5, 6, 7, 8, 9, 10}. Breast feeding is safe for women in MMT and their babies and

supported by the American Academy of Pediatrics⁶⁴. It is recommended that women who are HIV-1 positive should not breastfeed due to concerns about mother-to-child transmission⁶⁵.

No cardiac or significant electrocardiographic abnormalities related to methadone treatments were noted in the early or more recent prospective or cross-sectional studies of medical safety for almost 40 years. In the last six to eight years, and predicted from *in vitro* calcium channel focused studies of opiate effects, issues have been raised regarding possible cardiac effects of methadone. Higher doses of methadone (>200 to around 400 mg/day) in MMT and chronic pain patients have been reported to be potentially associated with prolongation (>500msec) of the QTc interval on electrocardiogram (EKG) and possibly with Torsades de pointes, a potentially life-threatening arrhythmia⁶⁶. Many of these patients had other risk factors⁶⁷ including taking other medications such as anti-retrovirals⁶⁸ or antidepressants⁶⁹ 70, which are known to prolong QTc, or abusing other drugs. The effect may or may not be related to dose or methadone serum concentration⁶⁹, and may become clinically significant (generally if >500 ms)⁷⁰. It may be prudent for all patients requiring a chronic methadone dose >150 mg to have a baseline EKG and then to be monitored periodically afterward; also high risk patients with prior QTc prolongation should be monitored⁷¹.

Before initiating methadone treatment, it is important to make sure that the patient is in fact opioid dependent, which can be established by history, clinical exam and urine toxicology. Opioids have a number of potential side effects; however when appropriate doses of methadone are used below the level of tolerance developed to each effect, the effects are minimal. If the dose is increased too rapidly, sedation, the major side effect observed in an opioid-tolerant patient, may occur. In an opiate-naïve patient, initial side effects of methadone may include drowsiness, nausea and constipation, while emesis, itching and dizziness are less common⁷². However, in a properly managed long-term MMT patient, the two most significant side effects are constipation, to which tolerance usually occurs over the course of three years, and sweating, which persists in about 50% of patients⁷³. Constipation and the other side effects tend to lessen due to the development of tolerance, defined as a loss of an effect over time after repeated use. Tolerance develops at different rates for the side effects of methadone, occurring over days, weeks or years⁷³. Dosing must be titrated to the tolerance of the individual patient to avoid somnolence, an early sign of CNS depression. As with all opioids, methadone must be used prudently in patients with compromised respiratory function.

Accidental Methadone Overdose and its Medical Management

Methadone should always be provided in childproof containers. However, in an opioid-naïve child, or when methadone is taken illicitly by an adult who is opioid-naïve or with low tolerance, methadone overdose may occur, characterized by stupor or coma, or respiratory depression, which can lead to death. Decreased response to carbon dioxide in centers of specific areas of the pons and medulla of the brain may lead to CO₂ retention⁷⁴. Depression of the mental status is accompanied by suppressed gag reflex, predisposing the patient to aspiration of gastric contents into the lungs. Constriction of the pupil occurs, which is the result of parasympathetic nerve excitation⁷⁵.

A methadone overdose can be effectively treated with an opioid antagonist; however the pharmacokinetic profile of each drug is critical. Naloxone has a half-life of 30 minutes; thus more than one dose will be needed. When overdose occurs due to use of methadone in an opioid-naïve or mildly tolerant person, repeated intravenous doses or a constant infusion of naloxone may be needed for more than 24 hours⁷⁵ to prevent relapse into coma⁵⁸.

Retention in Methadone Treatment – Women's Issues

A substantial body of research exists, documenting that methadone, when given as maintenance, is the most effective treatment for heroin/opiate addiction. When given in adequate daily doses, methadone will: decrease heroin use^{76, 77, 78, 79}; decrease criminal behavior^{80, 81, 82}; decrease spread of HIV/sexually transmitted diseases (STDs) and other blood-borne diseases, i.e., hepatitis C^{83, 84, 85, 86}; decrease mortality^{82, 87, 88}; possibly decrease secondary drug use^{89, 90, 91}; increase retention in treatment^{92, 93}; increase stable family relationships; and increase employment and participation in job training⁹⁴.

These benefits can only occur if patients are retained in treatment. Dr. Vincent Dole of The Rockefeller Institute reported that 80–90% of patients discharged or lost to treatment returned to illicit substance abuse and all its inherent risks. The early literature demonstrated that when patients are given adequate doses of methadone, then between 80–120mg, they are more likely to be retained in treatment, and to reduce their illicit opiate use, particularly in the first six months of treatment^{92, 95, 96, 97, 98}. Adequate dosing, tailored to the patient's individual need, is the dose that when administered will block superimposed short-acting narcotic euphoria, prevent withdrawal symptoms, and reduce or eliminate drug craving for twenty-four hours or more⁹⁹.

In the mid- to late 1960s, during the first six years of MMT clinical trials, the Rockefeller team and their collaborators titrated over 2205 patients to daily doses of methadone equaling 80–120mg¹⁰⁰. At that dose level overall retention in treatment was 82%, arrest rates dropped from 20%/year prior to treatment to less than 3%/year after treatment, and employment rates reached 70%, as reported by Gearing and associates¹⁰¹. Nearly twenty years later, in 1983, Hargreaves¹⁰² reviewed twenty-two methadone studies and concluded that a 100mg dosage was associated with a more positive outcome than a 50mg dosage in the first five to ten months of MMT. Other studies have shown an inverse relationship between the frequency of heroin use and the dose of methadone. In the 1990s, Strain, Stitzer, Liebson and Bigelow¹⁰³ followed 247 intravenous opioid-dependent patients for 20 weeks. Patients were assigned to 0mg, 20mg or 50mg methadone groups. The 50mg group had greater retention in MMT (52%, 42% and 21%) as well as less opioid-positive urines (56%, 68%, and 74%). In 2002, Maxwell and Shinderman¹⁰⁴ reported the clinical courses of 245 MMT patients over 152 weeks. Patients on methadone doses greater than 100 mg per day had better retention rates (61.1% vs. 46.3%) and lower rates of opiate-positive urine toxicologies (16% vs. 36.6%) than patients treated with less than 100 mg per day. Peles and colleagues⁹², in an MMT program in Israel, prospectively studied 492 patients and found that factors predicting retention in treatment were methadone doses of 100mg or greater, negative urine toxicology for opiates, and being a parent.

Other confirmatory studies were conducted in Denver, Colorado, and Ireland. In the former study, Booth and colleagues concluded that higher methadone doses, as well as free treatment, increased retention rates in programs¹⁰⁵. In the latter study, Kamal and colleagues found that patients enrolled in MMT with higher methadone doses were more likely to be opiate abstinent¹⁰⁶.

Despite this compelling research, by the 1980s more than 40% of MMTP patients were receiving daily methadone doses of less than 40 mg. Even as late as 2005¹⁰⁷, Brady and colleagues found that more than two thirds of methadone patients nationwide were receiving below 60mg/day.

Drug and Alcohol Codependency in Female Methadone-maintained Patients

Cocaine

Beginning in the 1980s and 90s a high prevalence of cocaine abuse among patients entering methadone treatment was reported in the literature^{108, 109}. Kosten's study reported a 74% rate of recent cocaine use among a cohort of New York City MMT admissions from 1978 to 1980, and the Drug Abuse Treatment Outcome Studies (DATOS), which tracked MMT admissions during 1990–1995, reported a 42% prevalence. The latter statistic appears steady over the past decade, as 2007 statistics obtained for New York City MMT programs show that 44% of patients self-reported cocaine as the secondary drug of abuse on admission. Interestingly, females in NYC reported a higher frequency (49.4%) than males (41.6%) (New York State Office of Alcoholism and Substance Abuse Services Client Data System)¹¹⁰. A higher rate of cocaine-positive urine samples was also observed among females (20%) as compared to males (11.3%) in Israel during the first month of admission to methadone maintenance¹¹¹, notable in a country where cocaine abuse was not prevalent until a period of time after the clinic opened in 1993. The role of the mu-opioidergic system in cocaine craving and relapse was first elucidated by studies in rodent models demonstrating upregulation of mu-opioid receptors in rats following chronic intermittent “binge” cocaine administration and persisting throughout early withdrawal^{112, 113}. These findings were corroborated by PET studies in humans showing an increase in mu-opioid binding immediately following chronic cocaine use, and persisting for up to four weeks during abstinence^{114, 115}. Treatment outcome studies have shown that a majority of patients demonstrate significant reductions in cocaine use during long-term MMT^{81, 109, 116}, and at least two studies have found an association between higher methadone levels and cessation of cocaine use^{91, 116, 117}.

Despite this success, a percentage of long-term methadone-maintained patients, reported from 15% to 25%, continued chronic cocaine abuse^{108, 116, 118}. Treatment strategies employed to reduce cocaine use in these patients vary by program with a majority of MMT programs surveyed by Kolar and colleagues instituting more frequent counseling and urine toxicology submission in response to positive cocaine tests¹¹⁸. However, as overall heroin abuse is mitigated and cocaine abuse reduced by MMT, it seems inappropriate to discharge patients due solely to continued cocaine use.

Alcohol

Alcohol abuse at treatment entry and during long-term methadone maintenance is more difficult to assess since data is frequently derived from patient self-report as opposed to breathalyzer or urine testing¹¹⁹. Drug Abuse Treatment Outcome Studies (DATOS) showed that 20–50% of all methadone maintenance patients in the United States display alcohol-related problems¹⁰⁹. Overall, women in methadone maintenance have been shown to abuse alcohol to a lesser extent than men. A recent Swedish study found that 39% of females as compared to 54% of males admitted to MMT had been treated for an alcohol-related diagnosis and/or had positive laboratory tests indicating recent moderate to high alcohol usage¹¹⁹. New York City statistics for 2007 corroborate this; 5.5% of females as compared to 7.7% of men self-reported alcohol as the secondary substance of abuse on admission¹¹⁰.

Early prospective studies performed on 129 long-term methadone-maintained men and women demonstrated that even with 25% of the cohort reporting consumption of four or more alcoholic drinks per day, there were no significant changes in liver enzymes or serum protein values after three years on methadone³⁰. Therefore, methadone maintenance does not potentiate alcohol-induced hepatotoxicity. The Swedish study found a significant association between drinking alcohol and relapse to illicit drugs, particularly benzodiazepines and cannabis among females,

but no such association was found in males¹¹⁹. Thus, clinicians should make an effort to screen for alcohol abuse in MMT females on admission and plan treatment accordingly.

In contrast to the observation that methadone can reduce illicit drug use, MMT does not appear to affect rates of alcohol use from admission to one year follow-up¹²⁰. Therefore, providers may want to consider treatment of MMT patients for whom heavy alcohol use is a problem. Most studies show limited efficacy of disulfiram, an acetaldehyde dehydrogenase inhibitor which when combined with alcohol induces adverse effects, attributed to poor compliance with self-administration¹²¹. However, as MMT provides a favorable setting for the supervised dispensing of disulfiram, it may be a helpful adjunct for reducing alcohol intake in certain motivated MMT patients. Disulfiram is metabolized by the liver and prescribing it to patients with abnormal liver tests is not recommended. It is advised that liver enzymes be obtained prior to initiating treatment, and every two weeks thereafter for the first 2–3 mos¹²¹.

Acamprosate, an antiglutaminergic approved by the FDA in 2005, is primarily excreted by the kidneys and therefore may be a better option for patients with compromised liver function¹²². While shown to effect complete abstinence from alcohol in only about a third of patients; female gender was not found to be associated with treatment outcome in a study where potential predictive variables were examined¹²³.

Benzodiazepines

A study which examined gender-based disparities in benzodiazepine use among those in MMT did not find significant differences between males and females at admission. However, females were less likely than males (18.8% vs. 29.9%) to initiate benzodiazepine use during the first year in MMT than males¹¹¹. Benzodiazepines share some of the cytochrome P450 metabolic pathway with methadone, and therefore have the potential to cause interactions. While several studies suggested an enhanced subjective effect of methadone when taken concurrently with benzodiazepines, there has been no evidence that benzodiazepines increase serum methadone levels, and the effects are most likely due to increased CNS depression¹²⁴. Reported interventions for benzodiazepine abuse during MMT include prescribing a single, long-acting benzodiazepine (clonazepam) to replace the patient's total daily illicit dose, which may or may not be administered by the clinic's medical staff¹²⁵ and/or increasing the daily methadone dose in response to patients' positive toxicology for benzodiazepines¹²⁴. Higher methadone doses were associated with better outcomes in successful detoxification from benzodiazepines for those patients who declined clonazepam maintenance in one study¹²⁵.

Cannabis

Information regarding the prevalence of marijuana abuse among MMT patients is less available in the literature as many MMT programs no longer include cannabis in the urine toxicology panel. This may be due in part to the publication of several studies in the 1990s, two of them derived from predominantly male cohorts, which showed no significant association between cannabis use and the use of other illicit drugs^{126, 127}. Studies reporting treatment outcomes with methadone maintenance have shown that overall use of cannabis, similar to that of other illicit drugs, declines with long-term methadone treatment¹²⁰. In addition, cannabis use was not found to decrease retention in MMT programs¹²⁸.

Medical Issues Specific to Women in MMTP

Women entering into methadone maintenance treatment present with a wide range of medical issues throughout their life spans. A recent study in Israel has shown that females are more likely to enter MMT at a younger age than males, with more than double the percentage of total female admissions occurring in the 18–30 age group as compared to males¹²⁹. Statistics

obtained for admissions in 2007 to New York City MMT programs indicated that 62% of all female admissions were women between 18–34 years as compared to 56% of the total male admissions in this age range.

Because of the relatively young age of entry into treatment, MMT programs have an opportunity to address contraception and pregnancy planning with women during intake and throughout treatment. Few studies have examined sexual activity and contraceptive practices in methadone-maintained females. Those that specifically addressed this topic reported the number of sexually active women in MMT ranged from 61% at a rural MMTP to 84.5% at an urban clinic; however birth control rates were similar in both MMT programs, with at least a third of sexually active women reporting no use of contraception^{130, 131}. In one study, Harding and colleagues interviewed a subset of seven women who did not use contraception, and cited a perceived low risk of pregnancy due to a variety of reasons: infrequent sex, a history of infertility, difficulties with male erection due to partner drug use and falsely assuming breastfeeding afforded protection against pregnancy. Altered menstrual cycles during drug use, and in early methadone maintenance were also mentioned by several women as a significant reason why they were not using contraception¹³¹.

Effects of illicit opiates on the menstrual cycle are well-documented, with early studies reporting that 30–54% of heroin-using women to have secondary amenorrhea^{59, 132}. In comparison, the prevalence of amenorrhea in a population of healthy, adult women has been estimated to be 2–4%^{133, 134}. Few researchers have examined the effects of methadone maintenance on menstrual regulation. Early data from our laboratory demonstrated that in a cohort of methadone-maintained females, 54% had reported amenorrhea on admission, while 83% of the subjects were reporting normal menses after an average methadone stabilization time of 2.7 years⁵⁹. More recently, Schmittner and colleagues found that 59% of women reporting pre-study secondary amenorrhea had resumed menses during a six-month period of methadone maintenance¹³⁵. No studies have found a correlation between methadone dose and menstrual dysfunction^{132, 135}.

Intravenous drug use (IVDU) forms the route of acquisition of up to half the cases of HIV infection among women in the U.S., while having had sex with a male IVDU accounts for almost 25% of new HIV cases¹³⁶. This risk of HIV acquisition underscores the need to assess sexual history in determining appropriate contraception with female methadone patients. The World Health Organization (WHO) reported that barrier methods differ in rates of pregnancy prevention for women in general, with condoms highest at 86–97%, diaphragms with contraceptive gel (84–94%) and cervical caps (68–91%), with the lower number representing typical use and the higher number corresponding to perfect (correct and consistent) use¹³⁷. While condoms are the only method to effectively prevent HIV transmission, diaphragms and cervical caps have been found to confer low level protection against chlamydia and gonorrhea. Pregnancy prevention rates with oral hormones range from 92–99%, injectable hormone preparations are 97–99.5%, and intrauterine devices 99.5%, but none of these methods offer protection against STDs. While there are no reports of medication interactions between the hormonal methods and methadone, the use of some medications prescribed for methadone-maintained females, such as anti-retrovirals and certain anticonvulsants, may reduce the effectiveness of hormonal preparations. In addition, certain co-morbid conditions, such as active viral hepatitis, may be a contraindication to prescribing hormonal preparations. Clinicians may access the WHO Medical Eligibility Criteria for Contraceptive Use¹³⁸ online at www.who.int/reproductive-health/publications/mec for guidance.

The substance abuse treatment population as a whole is aging, and an increasing percentage of women remain in treatment into middle age. As of 2000, 60% of all women in New York City MMT programs were between the ages of 35 and 54¹¹⁰. To date, only one researcher has

specifically examined menopausal symptoms in methadone-maintained females. Tuchman reported a similar prevalence of vasomotor symptoms (i.e. hot flashes and night sweats) among methadone-maintained women vs. other study populations, while a much larger percentage in the methadone-maintained group complained of insomnia. In a report by Tuchman and colleagues, ethnic differences were also noted as Hispanic methadone-maintained women had a higher degree of symptom reporting than African American or Caucasian women¹³⁹. Thus, it is important for clinicians to differentiate menopausal symptoms from opiate withdrawal and/or inadequate methadone dose in mid-life women.

Treatment Addressing Specific Needs of Women

A consensus exists in the addiction treatment literature that women have different substance abuse treatment needs than do their male counterparts and that lack of gender-specific services is a barrier to care. A strong positive correlation exists between troubled relationships, family violence, sexual abuse and poor self esteem as integral factors in substance abuse among women^{140, 141}. Also, a large percentage (25% to 57%) of women in drug treatment programs reported a history of intimate partner violence (IPV)^{142, 143, 144, 145}, compared to rates of 1.5% to 16% in community based samples^{146, 147}.

Women who use substances are more likely to report a history of emotional, sexual or physical abuse than men who use substances; this may impede or prevent the process of recovery. Unlike women with psychiatric problems, men in treatment who have a history of abuse appear to recover at rates similar to men without a history of abuse¹⁴⁸. The prevalence of diagnosed post-traumatic stress disorder (PTSD) ranges from 20% to 60% among women in substance abuse treatment^{149, 150}. Research has found an association between women experiencing IPV and heroin use¹⁴⁵. Female methadone patients report more depression and anxiety than males as well as more suicidal thoughts and attempts^{140, 141}.

In a study which examined the different perceptions of causal factors related to their substance abuse between men and women, women substance users indicated that domestic violence or incest had a greater impact on their substance use than men¹⁴⁰. Retention rates appear to be similar for males and females. Older female patients are more likely to remain in treatment longer; heroin users are less likely to be retained in a program^{92, 93, 129}; having children and less frequent use of benzodiazepines were also associated with long term retention^{92, 129}.

As a result of research showing that women have different substance abuse treatment needs than males, a women-only MMT program was established in 2000 within the Beth Israel Medical Center (BIMC). This program is named Billie's Place in memory of Billie Holiday. Billie Holiday, an African American female, has been described as the most influential singer of the 20th century and is still considered the most famous of jazz singers. "Lady Day" was also a heroin addict and alcoholic, and died in 1959 at the age of 44 in a New York City hospital of complications of her addictions.

The BIMC-MMT program is the largest methadone maintenance program in the nation. It operates 18 clinics in two boroughs of NYC, with a patient census of 6,500. BIMC, the sponsor of the methadone maintenance program, is a full service acute care teaching hospital in Manhattan. It is accredited by the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), as is its network of methadone clinics. The methadone clinics comply with, and are overseen by, government agencies, Substance Abuse and Mental Health Services Administration (SAMHSA), the Drug Enforcement Agency (DEA), the New York State Department of Health, and the New York State Office of Substance Abuse Services (OASAS). All 18 clinics are in good standing with these agencies. All of BIMC's methadone clinics serve both men and women; however Billie's Place is the only gender-specific clinic.

The overall plan for Billie's Place was to establish a positive therapeutic relationship with the female patients, and quickly stabilize each patient's methadone dose, with the aims of decreasing or eliminating heroin use and promoting program retention and improvement in overall health status. At time of inception, and during a period of three years of its existence, Billie's Place provided an intensive day treatment program for predominantly African American and Hispanic/Latina women who were already in MMT, as well as new admissions who were HIV-1- positive or at high risk for HIV and other infectious diseases. Female IVDUs who were HIV-1-positive, or at high risk for HIV, had more complex medical and social problems than their male counterparts. Women's health is often complicated by obstetrical, gynecological, and family issues; women often choose to attend to their children's and partner's health care needs before their own. For women of color in particular, lay therapeutic practices combined with ethnic and/or cultural beliefs and attitudes may complicate their acceptance of mainstream healthcare. Also, for women with limited resources, lack of health insurance, transportation difficulties, and childcare are additional barriers to accessing substance abuse treatment and as well as other health care.

Billie's Place was originally established through a SAMHSA grant 5H79TI12162 awarded in 1999 and opened in 2000, with an initial capacity for fifty women. Formal services provided on site included MMT, co-dependency drug treatment and counseling, counseling and testing for HIV, complete gynecological examinations with initial testing for sexually-transmitted diseases, i.e., chlamydia and gonorrhea, HIV risk reduction counseling, tuberculosis screening and group counseling in the areas of sexual abuse, domestic violence and negotiating safer sex. Workshops in parenting, employment skills, and life skills training were provided. All services were sensitive to cultural backgrounds of patients and were offered in English and Spanish. Referrals were made to primary medical care and primary HIV medical care in clinics located in the community, or to BIMC services. Patients were screened for other STDs (syphilis) and hepatitis B and C, prenatal and postpartum care; family planning services, were also available through referral. Vocational services and educational programs were provided on site and through referrals.

The program focused on informal social activities as well. These included providing a social space where health education materials, as well as light reading, were available. A computer with internet access was available for patients' use. In addition, the women could use this space to socialize, eat light refreshments, and participate in structured weekly events.

The original staffing consisted of one program director, one case manager, two substance abuse counselors, one neighborhood outreach worker, one nurse practitioner, one registered nurse, and one administrative assistant.

Billie's Place successfully provided intensive partial day treatment, individualized case management, an inclusive and non-judgmental support network, and comprehensive, direct links to health care treatment and rehabilitation services. Although the grant from SAMSHA ended, Billie's Place continues to exist, as a separate women-only clinic (with markedly reduced staffing), within the BIMC MMT program. Direct inquiries for additional information regarding Billie's Place to Dr. Randi Seewald, Medical Director, BIMC MMTP, 160 Water Street, 24th floor, New York, NY 10038 rseewald@chnet.org

Acknowledgments

Funding support was received from the National Institutes of Health (NIH)-National Institute on Drug Abuse Research Center grant P60-DA05130, the NIH- National Institute of Mental Health grant MH79880, and the New York State Office of Alcoholism and Substance Abuse Services (OASAS) grant, C003189 (Kreek).

REFERENCES

1. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade: a medical technique for stopping heroin use by addicts. *Trans Assoc Am Phys* 1966;79:122–136. [PubMed: 4162906]
2. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. *Arch Intern Med* 1966;118:304–309. [PubMed: 4162686]
3. Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone methadone hydrochloride. *JAMA* 1965;193:646–650. [PubMed: 14321530]
4. Kreek MJ. Medical complications in methadone patients. *Ann NY Acad Sci* 1978;311:110–134. [PubMed: 369431]
5. Kreek, MJ. National Institute on Drug Abuse Symposium on Comprehensive Health Care for Addicted Families and Their Children. Washington, DC: Services Research Report (USGPO); 1977. The role of qualitative and quantitative analysis of drugs and their metabolites in maternal-neonatal studies; p. 67-73. #017-024-00598-3
6. Blake, DA.; Chappel, JN.; Kreek, MJ.; Meyer, KC.; Lyon Newmann, L.; Stimmel, B.; Stryker, J. Drug dependence in pregnancy: clinical management of mother and child - a guide to clinical management. Finnegan, LP., editor. Washington, DC: National Institute on Drug Abuse Research Monograph ADM, (USGPO); 1979. p. 9-678.
7. Kreek MJ. Disposition of narcotics in the perinatal period. Publication of AMERSA and The Career Teacher Program in Alcohol and Drug Abuse 1981-82;3:7–10.
8. Kreek, MJ. Opioid disposition and effects during chronic exposure in the perinatal period in man. In: Stimmel, B., editor. *Journal of Addictive Diseases*. Vol. 1. New York, NY: The Haworth Press, Inc; 1982. p. 21-53.
9. Kreek, MJ. Discussion on clinical perinatal and developmental effects of methadone. Cooper, JR.; Altman, F.; Brown, BS.; Czechowicz, D., editors. Vol. 1983. Washington, DC: National Institute on Drug Abuse Monograph Research in the Treatment of Narcotic Addiction: State of the Art; 1281. p. 444-453. DHHS Pub. # (ADM)83-1281
10. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. *J Pharmacol Exp Ther* 1985;233:1–6. [PubMed: 3981450]
11. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. *Nat Rev Drug Discov* 2002;1:710–726. [PubMed: 12209151]
12. Kreek MJ, Schlussman SD, Bart G, LaForge KS, Butelman ER. Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. *Neuropharmacology* 2004;47 Suppl 1:324–344. [PubMed: 15464148]
13. Kreek MJ, Schlussman SD, Reed B, Zhang Y, Nielsen DA, Levran O, Zhou Y, Butelman ER. Bidirectional translational research: Progress in understanding addictive diseases. *Neuropharmacology*. 2008 in press.
14. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. *J Pharmacol Exp Ther* 1999;288:260–269. [PubMed: 9862779]
15. Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ. Suppressed prolactin response to dynorphin A(1–13) in methadone maintained versus control subjects. *J Pharmacol Exp Ther* 2003;306:581–587. [PubMed: 12730354]
16. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. *Pharmacol Rev* 2005;57:1–26. [PubMed: 15734726]
17. Kreek MJ, LaForge KS. Stress responsivity, addiction, and a functional variant of the human muopioid receptor gene. *Molec Interv* 2007;7:74–78. [PubMed: 17468387]
18. Kreek MJ. Role of a functional human gene polymorphism in stress responsivity and addictions. *Clin Pharmacol Ther* 2008;83:615–618. [PubMed: 18323858]
19. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single nucleotide polymorphism in the human mu opioid receptor

- gene alters beta-endorphin binding and activity: possible implications for opiate addiction. *Proc Natl Acad Sci USA* 1998;95:9608–9613. [PubMed: 9689128]
20. Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, Ott J, Kreek MJ. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. *Mol Psychiatry* 2004;9:547–549. [PubMed: 15037869]
 21. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. *Neuropsychopharmacology* 2005;30:417–422. [PubMed: 15525999]
 22. Bart G, LaForge KS, Borg L, Lilly C, Ho A, Kreek MJ. Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the mu opioid receptor gene. *Neuropsychopharmacology* 2006;31:2313–2317. [PubMed: 16794569]
 23. Oosterhuis BE, LaForge KS, Proudnikov D, Ho A, Nielsen DA, Gianotti R, Barral S, Gordon D, Leal SM, Ott J, Kreek MJ. Catechol-*O*-methyltransferase (*COMT*) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. *Am J Med Genet B: Neuropsychiatr Genet* 2008;147B:793–798. [PubMed: 18270997]
 24. Borg, L.; Kravets, I.; Kreek, MJ. The pharmacology of long-acting as contrasted with short-acting opioids. In: Kosten, T.; Gorelick, D., editors. *Principles of addiction medicine*. 4th edition. New York: Lippincott Williams & Wilkins; 2008. in press
 25. Hachey DL, Kreek MJ, Mattson DH. Quantitative analysis of methadone in biological fluids using deuterium-labeled methadone and GLC-chemical-ionization mass spectrometry. *J Pharm Sci* 1977;66:1579–1582. [PubMed: 915734]
 26. Kreek MJ, Hachey DL, Klein PD. Stereoselective disposition of methadone in man. *Life Sci* 1979;24:925–932. [PubMed: 449601]
 27. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone - metabolism, pharmacokinetics and interactions. *Pharmacol Res* 2004;50:551–559. [PubMed: 15501692]
 28. Nilsson MI, Anggård E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. *Eur J Clin Pharmacol* 1982;22:343–349. [PubMed: 7106170]
 29. Wolff K, Hay AW, Raistrick D, Calvert R. Steady-state pharmacokinetics of methadone in opioid addicts. *Eur J Clin Pharmacol* 1993;44:189–194. [PubMed: 8453965]
 30. Kreek MJ. Plasma and urine levels of methadone. *NY State J Med* 1973;73:2773–2777.
 31. Dole VP, Kreek MJ. Methadone plasma level: Sustained by a reservoir of drug in tissue. *Proc Natl Acad Sci USA* 1973;70:10. [PubMed: 4509643]
 32. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. *Clin Pharmacokinet* 2002;41:1153–1193. [PubMed: 12405865]
 33. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, Kreek MJ. Opioid receptor imaging with PET and [¹⁸F]cyclofoxy in long-term methadone-treated former heroin addicts. *J Pharmacol Exp Ther* 2000;295:1070–1076. [PubMed: 11082442]
 34. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. *J Pharmacol Exp Ther* 1999;289:1048–1053. [PubMed: 10215686]
 35. Kreek MJ, Oratz M, Rothschild MA. Hepatic extraction of long- and short-acting narcotics in the isolated perfused rabbit liver. *Gastroenterology* 1978;75:88–94. [PubMed: 401102]
 36. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. *Clin Pharmacol Ther* 1981;30:353–362. [PubMed: 7273599]
 37. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin S-U, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. *N Engl J Med* 1984;310:1213–1217. [PubMed: 6709027]
 38. Borg L, Ho A, Peters JE, Kreek MJ. Availability of reliable serum methadone determination for management of symptomatic patients. *J Addict Dis* 1995;14:83–96. [PubMed: 8555281]
 39. Tong TG, Pond SM, Kreek MJ, Jaffery NF, Benowitz NL. Phenytoin-induced methadone withdrawal. *Ann Intern Med* 1981;94:349–351. [PubMed: 7224382]
 40. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. *N Engl J Med* 1976;294:1104–1106. [PubMed: 1256526]

41. Kreek MJ, Gutjahr CL, Garfield JW, Bowen DV, Field FH. Drug interactions with methadone. *Ann NY Acad Sci* 1976;281:350–371. [PubMed: 798526]
42. Cushman P, Kreek MJ, Gordis E. Ethanol and methadone in man: A possible drug interaction. *Drug Alcohol Depend* 1978;3:35–42.
43. Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. *J Affect Disord* 2007;99:213–220. [PubMed: 17055063]
44. Eap CB, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, Kosel M, Preisig M, Baumann P. Cytochrome 450 2D6 genotype and methadone steady-state concentrations. *J Clin Psychopharmacol* 2001;21:229–234. [PubMed: 11270921]
45. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ. *ABCB1* (*MDR1*) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. *Hum Mol Genet* 2008;17:2219–2227. [PubMed: 18424454]
46. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. *J Pain Palliat Care Pharmacother* 2005;19:13–24. [PubMed: 16431829]
47. Bowen, DV.; Smit, ALC.; Kreek, MJ. Fecal excretion of methadone and its metabolites in man: application of GC-MS. In: Daly, NR., editor. *Advances in mass spectrometry*. Vol. 7B. Philadelphia: Heyden & Son, Inc; 1978. p. 1634-1639.
48. Kreek MJ, Kalisman M, Irwin M, Jaffery NF, Schefflan M. Biliary secretion of methadone and methadone metabolites in man. *Res Commun Chem Pathol Pharmacol* 1980;29:67–78. [PubMed: 7403680]
49. Kreek MJ, Schechter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. *Drug Alcohol Depend* 1980;5:197–205. [PubMed: 6986247]
50. Kreek MJ, Bencsath FA, Field FH. Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: quantitation by direct probe chemical ionization mass spectrometry. *Biomed Mass Spectrom* 1980;7:385–395. [PubMed: 7470591]
51. Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. *Drug Intell Clin Pharm* 1987;21:773–783. [PubMed: 3322755]
52. Novick DM, Kreek MJ, Arns PA, Lau LL, Yancovitz SR, Gelb AM. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. *Alcohol Clin Exp Res* 1985;9:349–354. [PubMed: 3901806]
53. Tong TG, Benowitz NL, Kreek MJ. Methadone-disulfiram interaction during methadone maintenance. *J Clin Pharmacol* 1980;20:506–513. [PubMed: 7430415]
54. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. *J Acquire Immune Def Syndr* 2006;41:563–572.
55. Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. *J Clin Pharmacol* 2007;47:604–612. [PubMed: 17400820]
56. Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfecting with hepatitis C and HIV receiving methadone maintenance treatment. *Clin Ther* 2007;29:131–138. [PubMed: 17379053]
57. Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. *Clin Pharmacol Ther* 2005;77:214–224. [PubMed: 15735615]
58. McHugh, PF.; Kreek, MJ. The medical consequences of opiate abuse and addiction, and methadone pharmacotherapy. In: Brick, J., editor. *Handbook of the medical consequences of alcohol and drug abuse*. 2nd edition. New York: Haworth Press; 2008. p. 303-340.
59. Cushman, P.; Kreek, MJ. Some endocrinologic observations in narcotic addicts. In: Zimmerman, E.; George, R., editors. *Narcotics and the hypothalamus*. New York: Raven Press; 1974. p. 161-173.
60. Pond SM, Kreek MJ, Tong TG, Benowitz NL. Changes in methadone pharmacokinetics during pregnancy. *Clin Res* 1982;30:257A.

61. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. *J Addict Dis* 1999;18:51–61. [PubMed: 10631963]
62. Nanovskaya TN, Deshmukh SV, Nekhayeva IA, Zharikova OL, Hankins GD, Ahmed MS. Methadone metabolism by human placenta. *Biochem Pharmacol* 2004;68:583–591. [PubMed: 15242824]
63. Hieronymous TL, Nanovskaya TN, Deshmukh SV, Vargas R, Hankins GD, Ahmed MS. Methadone metabolism by early gestational age placentas. *Am J Perinatol* 2006;23:287–294. [PubMed: 16799915]
64. American Academy of Pediatrics: Committee on Drugs. The transfer of drugs and other chemicals into human milk. *Pediatrics* 2001;108:776–789. [PubMed: 11533352]
65. American Academy of Pediatrics: Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. *Pediatrics* 2008;122:1127–1134. [PubMed: 18977995]
66. Krantz MJ, Lewkowicz L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. *Ann Intern Med* 2002;137:501–504. [PubMed: 12230351]
67. Martell BA, Arnsten JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. *Ann Intern Med* 2003;139:154–155. [PubMed: 12859171]
68. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, Segura F. QT prolongation and Torsades de Pointes in patients with human immunodeficiency virus and treated with methadone. *Am J Cardiol* 2003;92:995–997. [PubMed: 14556883]
69. Martell BA, Arnsten JH, Krantz M, Gourevitch MN. Impact of methadone treatment of cardiac repolarization and conduction in opioid users. *Am J Cardiol* 2005;95:915–918. [PubMed: 15781034]
70. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. *Pharmacotherapy* 2005;25:1523–1529. [PubMed: 16232014]
71. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in Methadone Maintenance Treatment (MMT) patients – a cross-sectional study. *Addiction* 2007;102:289–300. [PubMed: 17222284]
72. Gutstein, HB.; Akil, H. Opioid analgesics. In: Brunton, L.; Lazo, JS.; Parker, KL., editors. *Goodman and Gilman's the pharmacological basis of therapeutics*. 11th Ed.. New York: McGraw-Hill; 2005. p. 547-590.
73. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. *JAMA* 1973;223:665–668. [PubMed: 4739193]
74. Shook JE, Watkins WD, Camporesi EM. Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. *Am Rev Respir Dis* 1990;142:895–909. [PubMed: 2171388]
75. Kleinschmidt, KC.; Wainscott, M.; Ford, MD. Opioids. In: Ford, MD.; Delaney, KA.; Ling, LJ.; Erickson, T., editors. *Ford: clinical toxicology*. 1st Ed.. Philadelphia: WB Saunders; 2001. p. 627-639.
76. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. *Am J Public Health* 1995;85:83–88. [PubMed: 7832267]
77. Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. *J Subst Abuse Treat* 2007;33:91–98. [PubMed: 17588494]
78. Deren S, Kang SY, Colón HM, Robles RR. Predictors of injection drug use cessation among Puerto Rican drug injectors in New York and Puerto Rico. *Am J Drug Alcohol Abuse* 2007;33:291–299. [PubMed: 17497552]
79. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. *Drug Alcohol Depend* 2008;94:199–206. [PubMed: 18243585]
80. Dole VP, Nyswander ME, Warner A. Successful treatment of 750 criminal addicts. *JAMA* 1968;206:2708–2711. [PubMed: 5754883]
81. Ball, JC.; Ross, A. *The effectiveness of methadone maintenance treatment: patients, programs, services, and outcomes*. New York: Springer-Verlag; 1991.

82. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction* 2005;100:820–828. [PubMed: 15918812]
83. National Institutes of Health. National Institutes of Health Consensus Development Statement (CDS): Management of hepatitis C. Bethesda, MD: National Institutes of Health; 2002 Jun 10–12. p. 132002, <http://consensus.nih.gov/cons/116/cdc.statement.htm>
84. Novick DM, Stenger RJ, Gelb AM, Most J, Yancovitz SR, Kreek MJ. Chronic liver disease in abusers of alcohol and parenteral drugs: a report of 204 consecutive biopsy-proven cases. *Alcohol Clin Exp Res* 1986;10:500–505. [PubMed: 3541673]
85. Des Jarlais DC, Marmor M, Cohen H, Yancovitz S, Garber J, Friedman S, Kreek MJ, Miescher A, Khuri E, Friedman SM, Rothenberg R, Echenberg D, O'Malley PO, Braff E, Chin J, Burtenol P, Sikes RK. Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome. *Morb Mortal Wkly Rep* 1984;33:377–379.
86. Novick DM, Khan I, Kreek MJ. Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. *United Nations Bulletin on Narcotics* 1986;38:15–25.
87. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction* 2008;103:462–468. [PubMed: 18190664]
88. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. *Drug Alcohol Depend* 1998;52:257–260. [PubMed: 9839152]
89. Magura S, Kang SY, Nwakeze PC, Demsky S. Temporal patterns of heroin and cocaine use among methadone patients. *Subst Use Misuse* 1998;33:2441–2467. [PubMed: 9781824]
90. Des Jarlais DC, Wenston J, Friedman SR, Sotharan JL, Maslansky R, Marmor M. Crack cocaine use in a cohort of methadone maintenance patients. *J Subst Abuse Treat* 1992;9:319–325. [PubMed: 1479629]
91. Peles E, Kreek MJ, Kellogg S, Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. *J Addict Dis* 2006;25:43–50. [PubMed: 16597572]
92. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. *Drug Alcohol Depend* 2006;82:211–217. [PubMed: 16219428]
93. Davstad I, Stenbacka M, Leifman A, Beck O, Korkmaz S, Romelsjö A. Patterns of illicit drug use and retention in a methadone program: a longitudinal study. *J Opioid Manag* 2007;3:27–34. [PubMed: 17367092]
94. Novick DM, Richman BL, Friedman JM, Friedman JE, Fried C, Wilson JP, Townley A, Kreek MJ. The medical status of methadone maintenance patients in treatment for 11–18 years. *Drug Alcohol Depend* 1993;33:235–245. [PubMed: 8261888]
95. Dole, VP.; Nyswander, ME. Addictive States. Association for Research in Nervous and Mental Disease. Baltimore: Williams & Wilkins Company; 1968. Methadone maintenance and its implication for theories of narcotic addiction; p. 359-366.
96. Kreek, MJ. The addict as a patient. In: Lowinson, JH.; Ruiz, P.; Millman, RB.; Langrod, JG., editors. Substance abuse: a comprehensive textbook. Baltimore: Williams & Wilkins; 1992. p. 997-1009.
97. Hiltunen AJ, Beck O, Hjemdahl P, Liljeberg P, Almström U, Brodin K, von Wachenfeldt J, Borg S. Rated well-being in relation to plasma concentrations of *l*- and *d*-methadone in satisfied and dissatisfied patients on methadone maintenance treatment. *Psychopharmacology (Berl)* 1999;143:385–393. [PubMed: 10367556]
98. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. *Addiction* 2005;100:1496–1509. [PubMed: 16185211]
99. Kreek, MJ. Tolerance and dependence: implications for the pharmacological treatment of addiction. In: Harris, LS., editor. Problems of Drug Dependence, 1986; Proceedings of the 48th Annual Scientific Meeting of the Committee on Problems of Drug Dependence. National Institute of Drug

Abuse Research Monograph Series; Washington, DC. 1987. p. 53-61. Supt of Docs, US Govt Print Off, DHHS Pub No(ADM) 87-1508

100. Dole, VP. Blockade with methadone. In: Clouet, DH., editor. Narcotic drugs biochemical pharmacology. New York: Plenum Press; 1971. p. 478-483.
101. Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. *Am J Epidemiol* 1974;100:101-112. [PubMed: 4850534]
102. Hargreaves, WA. Methadone dosage and duration for maintenance treatment. In: Cooper, J.; Altman, F.; Brown, B.; Czechowicz, D., editors. Research on the treatment of narcotic addiction: state of the art. Rockville, MD: National Institute on Drug Abuse; 1983. p. 19-79.
103. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. *Drug Alcohol Depend* 1993;33:105-117. [PubMed: 8261875]
104. Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. *J Addict Dis* 2002;21:1-12. [PubMed: 12094996]
105. Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. *Drug Alcohol Depend* 2004;74:177-185. [PubMed: 15099661]
106. Kamal F, Flavin S, Campbell F, Behan C, Fagan J, Smyth R. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. *Ir Med J* 2007;100:393-397. [PubMed: 17491538]
107. Brady TM, Salvucci S, Sverdlov LS, Male SA, Kyeyune H, Sikali E, DeSale S, Yu P. Methadone dosage and retention: an examination of the 60 mg/day threshold. *J Addict Dis* 2005;24:23-47. [PubMed: 16186081]
108. Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. *Am J Drug Alcohol Abuse* 1986;12:1-16. [PubMed: 3788892]
109. Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). *J Subst Abuse Treat* 2003;25:125-134. [PubMed: 14670518]
110. New York State Office of Alcoholism and Substance Abuse Services Client Data System (CDS) extract 09/2008
111. Peles E, Adelson M. Gender differences and pregnant women in a methadone maintenance treatment (MMT) clinic. *J Addict Dis* 2006;25:39-45. [PubMed: 16785218]
112. Unterwald E, Horne-King J, Kreek MJ. Chronic cocaine alters brain mu opioid receptors. *Brain Res* 1992;584:314-318. [PubMed: 1325249]
113. Bailey A, Gianotti R, Ho A, Kreek MJ. Persistent upregulation of mu-opioid, but not adenosine, receptors in brains of long-term withdrawn escalating dose "binge" cocaine-treated rats. *Synapse* 2005;57:160-166. [PubMed: 15945065]
114. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. *Nat Med* 1996;2:1225-1229. [PubMed: 8898749]
115. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M, Endres CJ, Dannals RF, Frost JJ. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. *Biol Psych* 2005;57:1573-1582.
116. Borg L, Broe DM, Ho A, Kreek MJ. Cocaine abuse sharply reduced in an effective methadone maintenance program. *J Addict Dis* 1999;18:63-75. [PubMed: 10631964]
117. Tennant F, Shannon J. Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations. *J Addict Dis* 1995;14:67-74. [PubMed: 7632748]
118. Kolar AF, Brown BS, Weddington WW, Ball JC. A treatment crisis: cocaine use by clients in methadone maintenance programs. *J Subst Abuse Treat* 7:101-107. [PubMed: 2388310]
119. Stenbacka M, Beck O, Leifman A, Romelsjö A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. *Drug Alcohol Rev* 2007;26:55-63. [PubMed: 17364837]

120. Fairbank JA, Duntelman GH, Condelli WS. Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. *Am J Drug Alcohol Abuse* 1993;19:465–474. [PubMed: 8273767]
121. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? *Addict* 2004;99:21–24.
122. Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. Pharmacotherapy of dual substance abuse and dependence. *CNS Drugs* 2007;21:213–237. [PubMed: 17338593]
123. Verheul R, Leher P, Geerlings PJ, Koeter MW, van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. *Psychopharmacology (Berl)* 2005;178:167–173. [PubMed: 15322728]
124. Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher dose methadone. *J Psychoactive Drugs* 1999;31:95–102. [PubMed: 10437990]
125. Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. *Aust N Z J Psychiatry* 2003;37:458–463. [PubMed: 12873331]
126. Saxon AJ, Calsyn DA, Greenberg D, Blaes P, Haver VM, Stanton V. Urine screening for marijuana among methadone-maintained patients. *J Addict* 1993;1:207–211.
127. Nirenberg TD, Cellucci T, Liepman MR, Swift RM, Sirota AD. Cannabis versus other illicit drug use among methadone maintenance patients. *Psych Addict Beh* 1996;10:222–227.
128. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. *Addiction* 2003;98:269–279. [PubMed: 12603227]
129. Schiff M, Levit S, Moreno RC. Retention and illicit drug use among methadone patients in Israel: a gender comparison. *Addictive Behaviors* 2007;32:2108–2119. [PubMed: 17335982]
130. Morrison C, Ruben S, Beeching N. Female sexual health problems in a drug dependency unit. *Int J STD AIDS* 1995;6:201–203. [PubMed: 7647124]
131. Harding C, Ritchie J. Contraceptive practice of women with opiate addiction in a rural centre. *Aust J Rural Health* 2003;11:2–6. [PubMed: 12603439]
132. Bai J, Greenwald E, Caternini H, Kaminetzky HA. Drug-related menstrual aberrations. *Obstet Gynecol* 1974;44:713–719. [PubMed: 4479341]
133. Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. *Ann Intern Med* 1998;129:229–240. [PubMed: 9696732]
134. Warren MP. Clinical review 77: Evaluation of secondary amenorrhea. *J Clin Endocrinol Metab* 1996;81:437–442. [PubMed: 8636244]
135. Schmittner J, Schroeder JR, Epstein DH, Preston KL. Menstrual cycle length during methadone maintenance. *Addiction* 2005;100:829–836. [PubMed: 15918813]
136. Fordyce EJ, Blum S, Balanon A, Stoneburner RL. A method for estimating HIV transmission rates among female sex partners of male intravenous drug users. *Am J Epidemiol* 1991;133:590–598. [PubMed: 2006646]
137. World Health Organization. Selected practice recommendations for contraceptive use. 2nd ed. 2004. Available at www.who.int/reproductive-health/publications/spr/index.htm
138. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. 2004. Available at www.who.int/reproductive-health/publication/mec. Retrieved November 4th, 2008
139. Tuchman E. Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment. *Soc Work Health Care* 2007;45:43–62. [PubMed: 17954448]
140. Lev-Wiesel R, Shuval R. Perceived causal and treatment factors related to substance abuse: gender differences. *Eur Addict Res* 2006;12:109–112. [PubMed: 16543747]
141. Rowan-Szal GA, Chatham LR, Joe GW, Simpson DD. Services provided during methadone treatment: a gender comparison. *J Subst Abuse Treat* 2000;19:7–14. [PubMed: 10867295]
142. Brewer DD, Fleming CB, Haggerty KP, Catalano RF. Drug use predictors of partner violence in opiate-dependent women. *Violence Vict* 1998;13:107–115. [PubMed: 9809391]

143. Chermack ST, Fuller BE, Blow FC. Predictors of expressed partner and non-partner violence among patients in substance abuse treatment. *Drug Alcohol Depend* 2000;58:43–54. [PubMed: 10669054]
144. El-Bassel N, Gilbert L, Frye V, Wu E, Go H, Hill J, Richman BL. Physical and sexual intimate partner violence among women in methadone maintenance treatment. *Psychol Addict Behav* 2004;18:180–183. [PubMed: 15238060]
145. El-Bassel N, Gilbert L, Wu E, Go H, Hill J. Relationship between drug abuse and intimate partner violence: a longitudinal study among women receiving methadone. *Am J Public Health* 2005;95:465–470. [PubMed: 15727978]
146. Caetano R, Nelson S, Cunradi C. Intimate partner violence, dependence symptoms and social consequences from drinking among white, black and Hispanic couples in the United States. *Am J Addict* 2001 Suppl:60–69. [PubMed: 11268822]
147. Tjaden, P.; Thoennes, N. Research in Brief. Washington, DC: United States Department of Justice; 2000. Extent, nature, and consequences of intimate partner violence: findings from the National Violence Against Women Survey; p. 7
148. Branstetter SA, Bower EH, Kamien J, Amass L. A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment. *J Subst Abuse Treat* 2008;34:208–214. [PubMed: 17596905]
149. Clark HW, Masson CL, Delucchi KL, Hall SM, Sees KL. Violent traumatic events and drug abuse severity. *J Subst Abuse Treat* 2001;20:121–127. [PubMed: 11306214]
150. Lincoln AK, Liebschutz JM, Chernoff M, Nguyen D, Amaro H. Brief screening for co-occurring disorders among women entering substance abuse treatment. *Subst Abuse Treat Prev Policy* 2006;1:1–9.